Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — ASX Small and Mid-Cap Conference (March 2022)
12 slides from Atomo Diagnostics's conference presentation, Mar 16, 2022
Slide 1: ASX Presentation March 2022
Atomo Diagnostics Limited Authorised by John Kelly, Managing Director Level 1, 3 -5 George Street, Leichhardt, NSW 2040 Australia For personal use only ASXPresentation March 2022 ATOMO ATOMO DIAGNOSTICS DIAGNOSTICS LIMITED LIMITED | :(ASX: | (ASX AT1) AT1)
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on communications transmitted or otherwise made available to the recipient in information available as at the date of this presentation. The information in this connection with the oppor
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is an innovative medical For personal use only device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to the global market Headquartered in Australia with international opera
Slide 4: Transforming the Self Testing Experience
TRANSFORMING THE SELF TESTING EXPERIENCE HIV For personal use only FROM Traditional ‘bits in a box’ LFA kits TO Atomo’s user-friendly all-in-one solution Issues with standard rapid test kits Advantages of Atomo devices Low user satisfaction and regulatory challenges INNOVATIVE: One fully-patented de
Slide 5: Atomo's Core Capabilities
ATOMO’S CORE CAPABILITIES The intersection between Medical Devices & Diagnostics For personal use only Less IP Intensive IP Intensive More sales focused Atomo DNA Core Functionality Devices Finished Products Customer Delivery Point-of-Care Self Testing • Blood collection • Galileo • HIV • Atomo Dire
Slide 6: Atomo's Leading Edge Device Platforms
ATOMO’S LEADING EDGE DEVICE PLATFORMS HIV For personal use only In Market Getting Ready for Market Galileo: supports professional & self test applications. WHO DaVinci Combo Self Test: Prequalified. • two unique assays in a single rapid test. • Metered sample volumes to each test strip • integrated
Slide 7: Simplifying Swab Testing
SIMPLIFYING SWAB TESTING* For personal use only Reduced user steps = Supports a broad range of swabs = lower error rates multiple test applications Integration of Atomo blister and automatic delivery = All of the sample delivered to the test simple and efficient = improved diagnostic performance Com
Slide 8: Atomo's Strategic Focus
ATOMO’S STRATEGIC FOCUS HIV For personal use only Core Capabilities Innovation, Co-development & Commercialisation (device design, usability, manufacturability, IP, regulatory, co-commercialisation) Markets Infectious Rapid Test Consumer Health Diseases Testing Devices & Wellness (HIV, COVID, Others
Slide 9: Telehealth: Established in the Market
TELEHEALTH: ESTABLISHED IN THE MARKET For personal use only Consumer Interest Investor Focus 76% Venture funding doubled now interested in for digital health 2019-2020, on track telehealth versus 11% to double again 2020-2021 usage in 2019 Provider Acceptance 64% $50B Regulatory and Reimbursement 80
Slide 10: Clinic at Home – The Next Healthcare Frontier
CLINIC AT HOME – THE NEXT HEALTHCARE FRONTIERtwo thirds of all clinical decisions are based on a diagnostic test For personal use only Strategic opportunity / home testing market: Rapidly emerging new market for eHealth enabled healthcare in the home, cannibalising lab/clinic-based models as well as
Slide 11: Corporate Snapshot
Corporate snapshot • Strong revenue growth, with H1 FY22 sales of $7.0m, 53% higher For personal use only than the prior comparable period • Quality balance sheet, with >$30m in assets including $15.8m in cash on hand and no debt • Strong cash receipts, with $7.7m in cash inflows from customers in H
Slide 12: Highlights
HIGHLIGHTS For personal use only A proven innovator: commercialised the world’s first fully integrated rapid blood tests for at-home use Expansion into swab testing market: development of an integrated swab test device incorporating the Atomo’s proprietary reagent blister and design know-how to mini
Atomo Diagnostics — ASX Small and Mid-Cap Conference (March 2022) on 6ix